Knight Therapeutics Reports Third Quarter 2021

 

  -- Achieves Record Quarterly Revenues --  

 

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

 

  Q3 2021 Highlights  

 

Financials

 
  • Revenues were $73,340, an increase of $28,101 or 62% over the same period in prior year.
  •  
  • Gross margin of $37,766 or 51% compared to $19,533 or 43% in the same period in prior year.
  •  
  • Adjusted EBITDA 1 was $17,334, an increase of $13,118 or 311% over the same period in prior year.
  •  
  • Net loss on financial assets measured at fair value through profit or loss of $21,301 for the three-month period ended September 30, 2021.
  •  
  • Net gain on financial assets measured at fair value through profit or loss of $16,644 for the nine-month period ended September 30, 2021.
  •  
  • Net loss was $8,586, compared to $17,492 net income in the same period in prior year.
  •  
  • Cash inflow from operations was $10,321, compared to a cash outflow from operations of $8,412 in prior year.
  •  

Corporate Developments

 
  • Re-launched a normal course issuer bid ("NCIB") in July 2021 and purchased 2,963,022 common shares for an aggregate cash consideration of $15,361.
  •  
  • Hired Monica Percario as Global VP Scientific Affairs, Daniela Marino as Global VP Legal and Compliance and Susan Emblem as Global VP Human Resources.
  •  

Products

 
  • Entered into exclusive supply and distribution agreement with Incyte Biosciences International Sàrl ("Incyte") for tafasitamab and pemigatinib in Latin America
  •  

Strategic Investments

 
  • Received distributions of $2,042 from strategic fund investments and realized a gain of $1,634.
  •  

Key Subsequent Events

 
  • Received $9,243 (US$7,460) as part of the final distribution from the liquidation of New Emerging Medical Opportunities Fund II Ltd.
  •  
  • Re-financed Bancolombia loan extending the maturity date from December 14, 2021 to October 26, 2026.
  •  
  • Purchased an additional 1,009,725 common shares through NCIB for an aggregate cash consideration of $5,258.
  •  

"I am excited to announce that for a second consecutive quarter, Knight achieved record quarterly results despite the ongoing challenges posed by the pandemic. During the last 9 months we executed on multiple fronts with our business development team closing Exelon ® , entering into an exclusive supply and distribution agreement with Incyte while the commercial team continuing to deliver on strong growth of our key brands and the operational teams executing on integration and systems implementation. Furthermore, we strengthened Knight's management team by adding a Global VP Scientific Affairs, a Global VP Legal and Compliance and a Global VP Human Resources, to continue delivering on growth and operational excellence," said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.

 

__________________________________________________________________________________
 
1
 
Adjusted EBITDA   is   not   a   defined term under IFRS, refer to   the definition   s   below for additional details   .  

 

 
SELECT FINANCIAL RESULTS REPORTED UNDER IFRS  
[In thousands of Canadian dollars]

 
                                                                                                                                                                                                                                                                               
     Change      Change  
   Q3-21    Q3-20    $   1     %   2    YTD-2    YTD-2    $   1     %   2   
         
Revenues   73,340    45,239   28,101   62 %   185,205    144,328   40,877   28 %
Gross margin   37,766    19,533   18,233   93 %   87,217    61,630   25,587   42 %
Selling and marketing   9,990    7,763   (2,227 ) 29 %   26,787    26,928   141   1 %
General and administrative   8,763    10,835   2,072   19 %   25,296    27,424   2,128   8 %
Research and development   3,793    2,967   (826 ) 28 %   9,196    8,035   (1,161 ) 14 %
Amortization of intangible assets   11,199    5,703   (5,496 ) 96 %   24,136    17,546   (6,590 ) 38 %
  Operating income (loss)    4,021    (7,735 ) 11,756   152 %   1,802    (18,303 ) 20,105   110 %
Interest income   (1,402    )   (3,188 ) (1,786 ) 56 %   (5,186    )   (11,515 ) (6,329 ) 55 %
Interest expense   959    822   (137 ) 17 %   2,287    3,070   783   26 %
Foreign exchange (gain) loss   (7,143    )   703   7,846   1,116 %   252    9,666   9,414   97 %
  Net (loss) income    (8,586    )   17,492   (26,078 ) 149 %   23,976    23,527   449   2 %
Basic net (loss) earnings per share   (0.07    )   0.14   (0.21 ) 150 %   0.19    0.26   (0.07 ) 27 %
  EBITDA   3    17,334    131   17,203   13,132 %   31,765    8,592   23,173   270 %
  Adjusted EBITDA   3    17,334    4,216   13,118   311 %   32,309    15,065   17,244   114 %
   1 A positive variance represents a positive impact to net income (loss) and a negative variance represents a negative impact to net income (loss)
   2 Percentage change is presented in absolute values
   3 EBITDA and adjusted EBITDA are non-IFRS measures, refer to section "Non-IFRS measures and reconciliation to adjusted EBITDA" below for additional details  
 

 

 

  SELECT FINANCIAL RESULTS AT CONSTANT CURRENCY  
[In thousands of Canadian dollars]

 
                                                                                                                                                                                                                                
   Q3-21    Q3-20     Variance    YTD-21     YTD-20     Variance  
  Excluding impact of IAS 29  
   Constant
Currency
  3  
   $   1     %   2      Constant Currency   3     $   1     %   2  
         
Revenues   71,613   44,235   27,378   62 %   182,880    137,000   45,880   33 %
Cost of goods sold   33,202   23,725   (9,477 ) 40 %   92,685    72,163   (20,522 ) 28 %
  Gross margin    38,411   20,510   17,901   87 %   90,195    64,837   25,358   39 %
  Gross margin (%)     54     %     46   %        49     %      47   %     
         
  Expenses          
Selling and marketing   9,666   7,501   (2,165 ) 29 %   26,345    25,699   (646 ) 3 %
General and administrative   8,100   9,914   1,814   18 %   23,935    25,547   1,612   6 %
Research and development   3,585   3,040   (545 ) 18 %   8,993    7,996   (997 ) 12 %
Amortization of intangible assets   10,262   5,466   (4,796 ) 88 %   22,469    15,923   (6,546 ) 41 %
  Operating income (loss)    6,798   (5,411 ) 12,209   226 %   8,453    (10,328 ) 18,781   182 %
  EBITDA   3    17,334   (695 ) 18,029   2,594 %   31,764    6,315   25,449   403 %
  Adjusted EBITDA   3    17,334   3,697   13,637   369 %   32,309    12,481   19,828   159 %
   1 A positive variance represents a positive impact to net income and a negative variance represents a negative impact to net income
   2 Percentage change is presented in absolute values
   3 Financial results at constant currency, EBITDA and adjusted EBITDA are non-IFRS measures, refer to section "Non-IFRS measures and reconciliation to adjusted EBITDA" below for additional details  
 

 

 

  SELECT BALANCE SHEET ITEMS  
[In thousands of Canadian dollars]

 
                                                         
     Change  
   09-30-21    12-31-20    $   
 
  %   1  
     
Cash, cash equivalents and marketable securities   156,029     392,225    (236,196 ) 60 %
Trade and other receivables   134,065     116,510    17,555   15 %
Inventory   74,912     56,505    18,407   33 %
Financial assets   189,743     193,955    (4,212 ) 2 %
Accounts payable and accrued liabilities   77,040   44,828    32,212   72 %
Bank loans   36,328   51,770    (15,442 ) 30 %
   1 Percentage change is presented in absolute values  
 

  Revenue: For the quarter ended September 30, 2021 revenues increased by $28,101 or 62% compared to the same prior year period. On a constant currency basis, revenues increased by $27,378 or 62%. The growth in revenues on a constant currency basis is explained as following:

 
  • An estimated increase in revenues of approximately $9,200 to $11,500 driven by the increased demand of certain of our infectious diseases products to treat invasive fungal infections associated with COVID-19. Of this amount, Knight estimates approximately $3,200 to $4,200 was not utilized during the quarter.
  •  
  • An increase in revenues of $9,905 driven by the acquisition of Exelon ® .
  •  
  • An increase in revenues of $6,047 or 76%, from $7,918 to $13,965, driven by the growth of our recently launched products, including Cresemba ® , Lenvima ® , Halaven ® , Nerlynx ® , Trelstar ® and certain BGx products.
  •  

  Gross margin: For the quarter ended September 30, 2021 gross margin increased from 43% to 51% explained by a change in product mix, lower inventory provision recorded in Q3-21 compared to Q3-20 offset by the re-negotiation of certain license agreements and the depreciation of the LATAM currencies. The gross margin would have been 54%, an increase of 3%, from 51% after excluding the adjustment of hyperinflation accounting in accordance with IAS 29.

 

  Selling and marketing: For the quarter ended September 30, 2021, selling and marketing increased by $2,227 or 29% and on a constant currency basis by $2,165 or 29% as compared to the same prior year period. Excluding, the allowance for expected credit losses, S&M increased by $1,857 or 25% due to increase in certain variable costs such as distribution and compensation as well as an increase in selling and marketing activities related to product launches and Exelon ® .

 

  General and administrative: For the quarter ended September 30, 2021, general and administrative expenses decreased by $2,072 or 19% and on a constant currency basis by $1,814 or 18% as compared to the same period in prior year. Excluding the non-recurring costs incurred in Q3-20 related to the Unified Tender Offer of $3,490, G&A increased by $1,676 or 17%. The increase is driven by an increase in the variable compensation and certain professional fees.

 

  Amortization of intangible assets: For the quarter ended September 30, 2021, amortization of intangible assets increased by $5,496, or 96%, mainly explained by the amortization of Exelon® acquired during Q2-21 partially offset by the depreciation of LATAM currencies.

 

  Interest income: Interest income is the sum of interest income on financial instruments measured at amortized cost and other interest income. For the quarter ended September 30, 2021, interest income was $1,402, a decrease of $1,786 or 56%, compared to the same prior year period, due to a decrease in interest rates, the average cash and marketable securities balances and a lower average loan balance.

 

  Interest expense: The interest expense relates to interest incurred on bank loans. For the quarter ended September 30, 2021 interest expenses was $959, an increase of $137 or 17% compared to the same period in the prior year due to higher interest rates.

 

  Adjusted EBITDA : For the quarter ended September 30, 2021 adjusted EBITDA increased by $13,118 or 311% and on a constant currency basis by $13,637 or 369%, compared to Q3-20. The growth in adjusted EBITDA is driven by an increase in gross of margin of $17,901 offset by an increase in operating expenses adjusted for acquisition and transaction costs as well as non-recurring expenses.

 

  Net loss or income: For the quarter ended September 30, 2021, net loss was $8,586 compared to net income of $17,492 for the same period last year. The variance mainly resulted from the above-mentioned items as well as a net loss on the revaluation of financial assets measured at fair value through profit or loss of $21,301 in the third quarter of 2021 versus a net gain of $12,873 in the prior year period mainly due to unrealized losses and gains on revaluation of the strategic fund investments.

 

  Cash, cash equivalents and marketable securities : As at September 30, 2021, Knight had $156,029 in cash, cash equivalents and marketable securities, a decrease of $236,196 or 60% as compared to December 31, 2020. The variance is primarily due to cash outflows related to the acquisition of Exelon®, the shares repurchased through NCIB and the repayments of bank loans offset by cash generated from operating activities.

 

  Financial assets: As at September 30, 2021, financial assets were at $189,743, a decrease of $4,212 or 2%, as compared to the prior period, mainly due to an increase of $17,063 due to mark-to-market adjustments offset by decrease of 16,652 due to net distributions in Knight's fund investments, loan repayments of $2,494 and disposal of equity investments of $2,624 during the period. Given the nature of the fund investments there could be significant fluctuations in the fair value of the underlying assets. During the quarter ended September 30, 2021, the Company recorded an unrealized loss of $20,629, as a result of the share price decrease of Singular Genomics Systems, Inc. ("SGS"), an investment held within Domain Associated LLC. Should the share price of SGS remain at this level, the Company would record a life to date unrealized gain of approximately $12,929 [USD 10,550] on this investment.

 

  Bank Loans: As at September 30, 2021, bank loans were at $36,328, a decrease of $15,442 or 30% as compared to the prior period, mainly due to loan repayment of $14,911.

 

  Product Updates  

 

On September 22, 2021, Knight entered into a definitive agreement with Incyte Biosciences International Sàrl, for the exclusive rights to distribute tafasitamab (sold as Monjuvi ® in the United States and Minjuvi ® in Europe) and pemigatinib (Pemazyre ® ) in Latin America. Under the terms of the agreement Knight will be responsible for seeking the necessary regulatory approvals and distributing both products in Latin America.

 

Knight expects to submit tafasitamab and pemigatinib in key LATAM countries in the second half of 2022.

 

  NCIB  

 

During the three-month and nine-month periods ended September 30, 2021, the Company purchased 2,963,022 and 7,844,438 common shares for $15,361 and $40,907, respectively.

 

Subsequent to quarter-end, the Company purchased an additional 1,009,725 common shares for an aggregate cash consideration of $5,258.

 

  Conference Call Notice  

 

Knight will host a conference call and audio webcast to discuss its third quarter results today at 8:30 am ET. Knight cordially invites all interested parties to participate in this call.

 

  Date: Thursday, November 11, 2021
Time: 8:30 a.m. ET
Telephone : Toll Free: 866-269-4264 or International 1-647-792-1240
Webcast:   www.gud-knight.com or Webcast  
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

 

  Replay: An archived replay will be available for 30 days at www.gud-knight.com   

________________________________________________________________________________________

 

  About Knight Therapeutics Inc.  

 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

 

  Forward-Looking Statement  

 

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

 

  CONTACT INFORMATION:  

 
                        
  Investor Contact:    
Knight Therapeutics Inc.   
Samira Sakhia   Arvind Utchanah
President & Chief Executive Officer   Chief Financial Officer
T: 514.484.4483   T. 514.484.4483
F: 514.481.4116   F. 514.481.4116
Email: info@knighttx.com    Email: info@knighttx.com  
Website: www.gud-knight.com    Website: www.gud-knight.com  
 

  

IMPACT OF HYPERINFLATION
 
[In thousands of Canadian dollars]

 

The Company applies IAS 29, Financial Reporting in Hyperinflation Economies, as the Company's Argentine subsidiaries used the Argentine Peso as their functional currency. IAS 29 requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy be adjusted based on an appropriate general price index to express the effects of inflation. If the Company did not apply IAS 29, the effect on the Company's operating income would be as follows:

 
                                                                                                                                                                                                                        
   Q3-21      YTD-21    
   Reported
under
IFRS
 
   Excluding
impact of
IAS 29
 
   Variance    Reported
under
IFRS
  
 
   Excluding
impact of
IAS 29
  
 
   Variance  
   $   1    %   2    $   1    %   2  
         
Revenues 73,340   71,613    1,727   2 % 185,205   182,880    2,325   1 %
Cost of goods sold 35,574   33,202    (2,372 ) 7 % 97,988   92,685    (5,303 ) 6 %
  Gross margin   37,766   38,411    (645 ) 2 % 87,217   90,195    (2,978 ) 3 %
  Gross margin (%)    51%     54%       47%     49%     
         
  Expenses          
Selling and marketing 9,990   9,666    (324 ) 3 % 26,787   26,345    (442 ) 2 %
General and administrative 8,763   8,100    (663 ) 8 % 25,296   23,935    (1,361 ) 6 %
Research and development 3,793   3,585    (208 ) 6 % 9,196   8,993    (203 ) 2 %
Amortization of intangible assets 11,199   10,262    (937 ) 9 % 24,136   22,469    (1,667 ) 7 %
  Operating Income   4,021   6,798    (2,777 ) 41 % 1,802   8,453    (6,651 ) 79 %
   1 A positive variance represents a positive impact to net income due to the application of IAS 29 and a negative variance represents a negative impact to net income due to the application of IAS 29
   2 Percentage change is presented in absolute values  
 

  
NON-IFRS MEASURES AND RECONCILIATION TO ADJUSTED EBITDA
 
[In thousands of Canadian dollars]

 

  Non-IFRS measures  

 

The Company discloses non-IFRS measures that do not have standardized meanings prescribed by IFRS. The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company's financial performance and in interpreting the effect of the GBT Transaction on the Company. Non-IFRS financial measures do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other companies.

 

  The Company uses the following non-IFRS measures:  

 

  Financial results at constant currency: Financial results at constant currency are obtained by translating the prior period results from the functional currencies to CAD using the conversion rates in effect during the current period. Furthermore, with respect to Argentina, the Company excludes the impact of hyperinflation and translates the results at the average exchange rate in effect for each of the periods.

 

Financial results at constant currency allow results to be viewed without the impact of fluctuations in foreign currency exchange rates thereby facilitating the comparison of results period over period. The presentation of results under constant currency is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.

 

  EBITDA: Operating income (loss) adjusted to exclude amortization and impairment of intangible assets, depreciation, PPA accounting adjustments, and the impact of IAS 29 (accounting under hyperinflation) but to include costs related to leases. In addition, EBITDA does not reflect the portion of GBT's results attributable to the non-controlling interests.

 

  Adjusted EBITDA: EBITDA adjusted for acquisition costs and non-recurring expenses.

 

Adjustments include the following:

 
  • With the adoption of IFRS 16, the lease payments of Knight are not reflected in operating expenses. The IFRS 16 adjustment approximates the cash outflow related to leases of Knight.
  •  
  • Acquisition costs relate to costs incurred on legal, consulting and advisory fees for the acquisition of GBT and the acquisition of products.
  •  
  • Other non-recurring expenses relate to expenses incurred by Knight that are not due to, and are not expected to occur in, the ordinary course of business.
  •  

For the three and nine-month periods ended September 30, the Company calculated EBITDA and adjusted EBITDA as follows:

 
                                                                                                                                                                                                                                             
     Change      Change  
   Q3-21    Q3-20     $ 1     %  
   2     YTD-21    YTD-20     $ 1     %     2  
  Operating income (loss)    4,021    (7,735 )   11,756   152 %    1,802    (18,303 )   20,105   110 %
Adjustments to operating (loss) income:           
Amortization of intangible assets   11,199    5,703    5,496   96 %    24,136    17,546    6,590   38 %
Depreciation of property, plant and
equipment and ROU assets
  1,796    1,382    414   30 %    4,778    4,916    (138 ) 3 %
Lease costs (IFRS 16 adjustment)   (744    )   (820 )   76   9 %    (2,141    )   (2,405 )   264   11 %
Impact of PPA accounting          0 %      865    (865 ) 100 %
Impact of IAS 29   1,062    1,601    (539 ) 34 %    3,189    5,973    (2,784 ) 47 %
  EBITDA   3    17,334    131    17,203   13,132 %    31,764    8,592    23,172   270 %
Acquisition and transaction costs     3,490    (3,490 ) 100 %    432    3,810    (3,378 ) 89 %
Other non-recurring expenses     595    (595 ) 100 %    113    2,663    (2,550 ) 96 %
  Adjusted EBITDA   3    17,334    4,216    13,118   311 %    32,309    15,065    17,244   114 %
  1   A positive variance represents a positive impact to net income   (loss)   and a negative variance represents a negative impact to net income   (loss)  
2   Percentage change is presented in absolute values  
3   EBITDA and adjusted EBITDA are non-IFRS measures, refer   above   for additional details   
 
 

 

 

  INTERIM CONSOLIDATED BALANCE SHEETS  
[In thousands of Canadian dollars]
[Unaudited]

 
                                                                                      
 

As at  
  
  September 30, 2021   December 31, 2020
   
  ASSETS    
  Current    
Cash and cash equivalents   92,490   229,592
Marketable securities   63,539   147,316
Trade receivables   69,003   62,515
Other receivables   21,356   12,413
Inventories   74,912   56,505
Prepaids and deposits   2,840   2,214
Other current financial assets   13,878   34,431
Income taxes receivable   5,052   7,115
  Total current assets    343,070   552,101
   
Marketable securities    15,317
Prepaids and deposits   3,443   4,208
Right-of-use assets   3,861   4,035
Property, plant and equipment   24,142   22,127
Investment properties   1,385   1,539
Intangible assets   359,432   156,547
Goodwill   75,999   77,725
Other financial assets   175,865   159,524
Deferred income tax assets   4,295   2,432
   
Other long-term receivables   43,706   41,582
   692,128   485,036
Assets held for sale   2,416   2,539
  Total assets    1,037,614   1,039,676
 

  

INTERIM CONSOLIDATED BALANCE SHEETS (continued)
 
[In thousands of Canadian dollars]
[Unaudited]

 
                                                                                                                        
 

As at  
  
  September 30, 2021    December 31, 2020  
   
  LIABILITIES AND EQUITY    
  Current    
Accounts payable and accrued liabilities   76,792    44,512  
Lease liabilities   1,472    1,875  
Other liabilities   2,040    1,291  
Bank loans   36,328    51,770  
Income taxes payable   11,389    13,559  
Other balances payable   4,532    1,053  
  Total current liabilities    132,553    114,060  
   
Accounts payable and accrued liabilities   248    316  
Lease liabilities   2,718    2,543  
Other balances payable   11,208    14,900  
Deferred income tax liabilities   18,290    21,616  
  Total liabilities    165,017    153,435  
   
  Shareholders' Equity    
Share capital   652,681    694,351  
Warrants   117    117  
Contributed surplus   21,470    18,731  
Accumulated other comprehensive loss   (1,202)    (1,503)  
Retained earnings   199,531    174,545  
  Total shareholders' equity    872,597    886,241  
  Total liabilities and   shareholders'   equity    1,037,614    1,039,676  
 

  

INTERIM CONSOLIDATED STATEMENTS OF INCOME (LOSS)
 
[In thousands of Canadian dollars, except for share and per share amounts]
[Unaudited]

 
                                                                                                                                                                                                                                                                                                                                             
   Three months ended September 30,   
 
   Nine months ended September 30,   
 
 
   2021    2020    2021    2020  
     
Revenues   73,340    45,239      185,205    144,328    
Cost of goods sold   35,574    25,706      97,988    82,698    
  Gross margin    37,766    19,533      87,217    61,630    
     
  Expenses      
Selling and marketing   9,990    7,763      26,787    26,928    
General and administrative   8,763    10,835      25,296    27,424    
Research and development   3,793    2,967      9,196    8,035    
Amortization of intangible assets   11,199    5,703      24,136    17,546    
  Operating income (loss)    4,021    (7,735)    1,802    (18,303)  
     
Interest income on financial instruments measured at amortized cost   (188)    (1,754)    (1,721)    (7,477)  
Other interest income   (1,214)    (1,434)    (3,465)    (4,038)  
Interest expense   959    822      2,287    3,070    
Other expense (income)   286    (243)    193    (133)  
Net loss (gain) on financial instruments measured at fair value through
profit or loss
  21,301    (12,873)    (16,644)    (22,642)  
Net gain on mandatory tender offer liability     (10,502)      (12,072)  
Realized gain on sale of asset held for sale         (2,948)  
Realized gain on automatic share purchase plan         (4,168)  
Foreign exchange (gain) loss   (7,143)    703      252    9,666    
(Gain) loss on hyperinflation   (92)    401      (214)    1,205    
  (Loss) income before income taxes    (9,888)    17,145      21,114    21,234    
     
  Income tax      
Current   1,351    (3,079)    1,293    1,386    
Deferred   (2,653)    2,732      (4,155)    (3,679)  
  Income tax recovery    (1,302)    (347)    (2,862)    (2,293)  
  Net (loss) income for the period    (8,586)    17,492      23,976    23,527    
     
  Attributable to:      
Shareholders of the Company   (8,586)    18,094      23,976    33,834   
Non-controlling interests     (602)      (10,307)
     
  Attributable to shareholders of the Company      
Basic net (loss) earnings per share   (0.07)    0.14      0.19    0.26    
Diluted net (loss) earnings per share   (0.07)    0.14      0.19    0.26    
     
  Weighted average number of common shares outstanding      
Basic   123,059,239    130,867,769      125,946,921    132,346,922    
Diluted   123,059,239    131,051,220      125,970,589    132,614,809    
 

  

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
 
[In thousands of Canadian dollars]
[Unaudited]

 
                                                                                                                                                                                                                                                                                                                            
   Three months ended September 30,   
 
   Nine months ended September 30,   
 
 
   2021    2020    2021    2020  
  OPERATING ACTIVITIES      
  Net (loss) income for the period    (8,586)    17,492    23,976    23,527  
Adjustments reconciling net income to operating cash flows:     
Depreciation and amortization   12,995    7,085    28,914    22,462  
Net gain on financial instruments   21,301    (12,873)    (16,644)    (22,642)  
Unrealized foreign exchange loss   (6,443)    703    (1,087)    9,666  
Other operating activities   (1,366)    (5,398)   689   (17,220)  
   17,901    7,009    35,848    15,793  
Changes in non-cash working capital and other items   (7,580)    (15,421)    4,089    (32,295)  
  Cash inflow (outflow) from operating activities    10,321    (8,412)    39,937    (16,502)  
     
  INVESTING ACTIVITIES      
Purchase of marketable securities     (662)    (47,895)    (37,778)  
Proceeds on maturity of marketable securities     32,440    146,896    226,999  
Investment in funds   (5,359)    (2,010)    (10,963)    (15,010)  
Acquisition of shares through mandatory tender offer     (170,855)      (170,855)  
Proceeds from distribution of funds   2,042    14,887    13,412    26,996  
Purchase of intangible assets   (1,705)    (1,191)    (220,198)    (14,024)  
Proceeds on sale of asset held for sale           77,000  
Other investing activities   (688)    (844)    4,000    (175)  
  Cash (outflow) inflow from investing activities    (5,710)    (128,235)    (114,748)    93,153  
     
  FINANCING ACTIVITIES      
Repurchase of common shares through Normal Course Issuer Bid   (17,864)    (3,736)    (40,907)    (35,001)  
Principal repayment on bank loans   (701)    (14,911)    (8,219)  
Proceeds from bank loans   2,325        2,325    10,998  
Other financing activities   (668)    (711)    (1,931)    (1,636)  
  Cash outflow from financing activities    (16,207)    (5,148)    (55,424)    (33,858)  
     
  (Decrease) increase in cash and cash equivalents during the
period
 
  (11,596)    (141,795)    (130,235)    42,793  
Cash and cash equivalents, beginning of the period   102,582    359,593    229,592    174,268  
Net foreign exchange difference   1,504    293    (6,867)    1,030  
  Cash and cash equivalents, end of the period    92,490    218,091    92,490    218,091  
     
Cash and cash equivalents     92,490    218,091  
Short-term marketable securities     63,539    158,944  
Long-term marketable securities       15,317  
  Total cash, cash equivalents and marketable securities      156,029    392,352  
 

  Primary Logo 

 

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×